Helios Equity Fund

Healios is a leading Japanese biotechnology company specializing in the development of regenerative medicine and cell therapies using induced pluripotent stem cell (iPSC) technology. The company's primary focus is on addressing high unmet medical needs in areas such as ophthalmology, neurology, and organ dysfunction. Healios is currently advancing several late-stage clinical programs, including MultiStem (HLCM051) for the treatment of ischemic stroke and acute respiratory distress syndrome (ARDS). Additionally, the company is leveraging its proprietary iPSC platform to develop next-generation therapies, including universal donor cells and immune cell therapies for oncology.